Peak Pharmaceuticals Receives Favorable Research Report By SeeThruEquity

BOULDER, CO--(Marketwired - January 30, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: CTCO) ("Peak Pharma" or the "Company"), a growth stage company aiming to become a leader in the research, development, sales and marketing of safe, all-natural, hemp-based, medicinal therapies and supplements (Nutraceuticals) for both humans and animals, is pleased to advise of a research report just released by SeeThruEquity (www.seethruequity.com), an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, Zack's and Thomson Estimates, one of the leading estimates platforms on Wall Street.

Ajay Tandon, CEO of SeeThruEquity, comments, "We see material growth potential for Peak Pharma in the upcoming quarters and are initiating coverage with a 12-month price target of $1.26 per share." The report, available at Peak Pharma Initiation Report, highlights and makes particular note of the opportunities presented by the Company's entry into the nutraceutical sector, given the scope of the large market segment and its "immense potential."

Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang states, "It's a real pleasure to have received such a balanced and favorable report from Mr. Tandon and his team at SeeThruEquity. When we engaged to present at the SeeThruEquity Investor Forum in November, we were apprised that a report would be forthcoming as part of their service and we are very pleased by their fair and positive assessment of our efforts to-date which validates our business strategy and truly motivates us towards further success."

All third party statements regarding recommendations and price targets regarding the Company's common stock are expressly not endorsed by the Company. Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.peakpharma.com.

About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distributes its research to an internal database of opt-in investors. They also contribute estimates to Thomson Estimates, one of the leading estimates platforms on Wall Street. For more information visit www.seethruequity.com.

About Peak Pharmaceuticals, Inc. (OTCQB: CTCO)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based nutraceutical and supplement products for the human and animal health markets. The Company aims to become a global leader in the research, development, sales and marketing of medicinal hemp and cannabinoid products. For more information visit www.peakpharma.com and follow us on Facebook, Twitter and LinkedIn.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. In addition, all third party statements regarding recommendations and price targets regarding the Company's common stock are expressly not endorsed by the Company. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.